NO20015314L - Steroidderivater - Google Patents

Steroidderivater

Info

Publication number
NO20015314L
NO20015314L NO20015314A NO20015314A NO20015314L NO 20015314 L NO20015314 L NO 20015314L NO 20015314 A NO20015314 A NO 20015314A NO 20015314 A NO20015314 A NO 20015314A NO 20015314 L NO20015314 L NO 20015314L
Authority
NO
Norway
Prior art keywords
steroid derivatives
steroid
derivatives
Prior art date
Application number
NO20015314A
Other languages
English (en)
Other versions
NO20015314D0 (no
Inventor
Shutsung Liao
Ching Song
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Publication of NO20015314D0 publication Critical patent/NO20015314D0/no
Publication of NO20015314L publication Critical patent/NO20015314L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20015314A 1999-04-30 2001-10-30 Steroidderivater NO20015314L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13172899P 1999-04-30 1999-04-30
US19186400P 2000-03-24 2000-03-24
PCT/US2000/011243 WO2000066611A1 (en) 1999-04-30 2000-04-27 Steroid derivatives

Publications (2)

Publication Number Publication Date
NO20015314D0 NO20015314D0 (no) 2001-10-30
NO20015314L true NO20015314L (no) 2001-12-27

Family

ID=26829742

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015314A NO20015314L (no) 1999-04-30 2001-10-30 Steroidderivater

Country Status (13)

Country Link
US (2) US6645955B1 (no)
EP (1) EP1189922A4 (no)
JP (1) JP2002543216A (no)
KR (1) KR20020028876A (no)
CN (1) CN1187364C (no)
AU (1) AU775630B2 (no)
BR (1) BR0010197A (no)
CA (1) CA2372493A1 (no)
IL (1) IL146223A0 (no)
MX (1) MXPA01011070A (no)
NO (1) NO20015314L (no)
NZ (1) NZ515810A (no)
WO (1) WO2000066611A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028880A2 (en) * 2000-10-06 2002-04-11 Aeson Therapeutics Inc. Compounds useful for treating hypertriglyceridemia
US20020116731A1 (en) * 2000-12-11 2002-08-22 Allen Keith D. Transgenic mice containing retinoid X receptor interacting protein gene disruptions
GB0101933D0 (en) * 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
JP2005508281A (ja) * 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
TW200300078A (en) * 2001-11-08 2003-05-16 Univ Chicago Method of treating disorder related to high cholesterol concentration
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
WO2003086303A2 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
CA2492906A1 (en) * 2002-07-19 2004-01-29 Pascal Druzgala Materials and methods for treating hypercholesterolemia
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
WO2005101011A2 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
CA2568857A1 (en) * 2004-06-24 2006-01-05 Galapagos N.V. Lxr agonists to promote bone homeostasis
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
KR101021828B1 (ko) * 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
JP2007035169A (ja) * 2005-07-27 2007-02-08 Matsushita Electric Ind Co Ltd 半導体記憶装置
US20090117155A1 (en) * 2006-05-26 2009-05-07 Jay Rappaport Treatment of hiv-1 by modulation of vpr activation of the m-csf promoter
WO2009038110A1 (ja) 2007-09-19 2009-03-26 Nagoya Industrial Science Research Institute 神経栄養因子様作用剤
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
CN101514222B (zh) * 2009-04-09 2011-08-03 中国人民解放军第二军医大学 总合草苔虫中一种甾体类化合物及其用途
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
CN102071246A (zh) * 2009-08-27 2011-05-25 北京科技大学 新型中药制剂的开发与评价
CA2811145A1 (en) 2010-09-07 2012-03-15 Snu R&Db Foundation Sesterterpene compound and use thereof
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EP3239163A1 (en) * 2012-04-12 2017-11-01 Virginia Commonwealth University A novel cholesterol metabolite, 5-cholesten-3,25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
CN103570790B (zh) * 2012-08-07 2016-06-01 中国科学院上海药物研究所 原人参二醇衍生物及其制备方法、包含该衍生物的组合物及其用途
PE20161405A1 (es) 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CN105963307B (zh) * 2016-05-06 2019-08-09 深圳以诺生物制药有限公司 一种罗汉果醇衍生物单体及其组合物的用途
IT201600068742A1 (it) * 2016-07-01 2018-01-01 Bar Pharmaceuticals Soc A Responsabilita Limitata Derivati dell'acido iodesossicolico e loro uso
SI3494125T1 (sl) 2016-08-02 2022-10-28 Virginia Commonwealth University Sestavki, ki vsebujejo 5-holesten-3, 25-diol, 3-sulfat(25HC3S) ali njegovo farmacevtsko sprejemljivo sol in vsaj en cikličen oligosaharid
CN107669688B (zh) * 2017-10-26 2020-02-14 河南中医药大学 3β-乙酰氧基-7,25-甘遂二烯-24R-醇在脂异常与糖尿病综合防治中的应用
JP2021504315A (ja) 2017-11-21 2021-02-15 ルジェニクス，インコーポレーテッド 多形及びその使用
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
CN111087441B (zh) * 2020-01-08 2021-06-22 黑龙江中医药大学 核桃青皮中一种三萜化合物的制备方法和应用
CN111349134B (zh) * 2020-04-23 2021-08-20 黑龙江中医药大学 核桃青皮中一种达玛烷型三萜化合物的制备方法
KR20220004451A (ko) * 2020-07-03 2022-01-11 연세대학교 산학협력단 지방간 질환의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698853A (en) 1951-08-11 1955-01-04 Monsanto Chemicals Oxidation of steroids
FR1482102A (fr) * 1966-03-31 1967-05-26 Centre Nat Rech Scient Nouveaux dérivés de stéroïdes et procédé de préparation
US3784598A (en) * 1972-01-20 1974-01-08 Ciba Geigy Corp Process for the conversion of a 3-hydroxy-5,6-oxido group of a steroid into a delta4-3-oxo group
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US3887545A (en) * 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4006172A (en) * 1976-04-26 1977-02-01 The Upjohn Company Process for 7-keto-Δ5 -steroids
US4125544A (en) 1977-06-09 1978-11-14 G. D. Searle 20/22/23/24-Oxa-7-oxocholesterols and esters thereof
US4193930A (en) 1977-08-29 1980-03-18 G. D. Searle & Co. 25-Alkyl-3β-hydroxycholest-5-en-7-ones and esters thereof
JPS563000A (en) 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4351767A (en) * 1981-06-29 1982-09-28 Kaiser Emil T Synthesis of 24,25-dihydroxycholesterol
US4639420A (en) * 1984-11-21 1987-01-27 Schaffner Carl P Method for the immunoanalysis of cholesterol epoxides
IT1212141B (it) * 1987-06-03 1989-11-08 So Ri Far S R L Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
US5151545A (en) * 1987-10-13 1992-09-29 Pfizer Inc. 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
US5562910A (en) 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5424463A (en) 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
JPH0749438B2 (ja) * 1990-10-31 1995-05-31 東京田辺製薬株式会社 タウリン抱合型胆汁酸の精製方法
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
IT1255486B (it) * 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la taurina
US5482935A (en) * 1993-01-05 1996-01-09 American Home Product Corporation Anti-atherosclerotic use of 17 alpha-dihydroequilin
TW289757B (no) 1993-05-08 1996-11-01 Hoechst Ag
IT1270853B (it) 1993-05-20 1997-05-13 Sanofi Elf Procedimento per la preparazione di derivati taurocolanici
CN1055929C (zh) 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
IT1274000B (it) 1994-04-06 1997-07-14 Alfa Wassermann Spa Derivati di acidi biliari utili nella terapia della calcolosi biliare da colesterolo e nelle patologie indotte da colestasi
DE69518515T2 (de) 1994-05-19 2001-04-19 Merck & Co Inc Oxidation von steroiden mit allylischen gruppen
US5583239A (en) * 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
BR9806989A (pt) * 1997-01-24 2000-03-14 Univ California Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
DE69940958D1 (de) * 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
AU2409600A (en) * 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
JP2005508281A (ja) * 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists
WO2003086303A2 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists

Also Published As

Publication number Publication date
US20040152681A1 (en) 2004-08-05
IL146223A0 (en) 2002-07-25
NZ515810A (en) 2004-05-28
EP1189922A1 (en) 2002-03-27
WO2000066611A1 (en) 2000-11-09
CA2372493A1 (en) 2000-11-09
CN1357003A (zh) 2002-07-03
KR20020028876A (ko) 2002-04-17
US6645955B1 (en) 2003-11-11
BR0010197A (pt) 2002-07-16
MXPA01011070A (es) 2003-06-30
AU4667200A (en) 2000-11-17
CN1187364C (zh) 2005-02-02
JP2002543216A (ja) 2002-12-17
EP1189922A4 (en) 2002-08-14
AU775630B2 (en) 2004-08-05
NO20015314D0 (no) 2001-10-30

Similar Documents

Publication Publication Date Title
NO20015314L (no) Steroidderivater
NO20000885L (no) 4-Fenyl-pyridin-derivater
NO20021077L (no) Amino-triazolopyridin-derivater
ATE263748T1 (de) Admantan-derivate
DE50010060D1 (de) Thiazolylamid-derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
NO20021803L (no) Isoksazolkarboksamid-derivater
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
ATE293592T1 (de) Resorcinderivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
NO20020212D0 (no) 3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no) Syklopentenon-derivater
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application